Stem Cell Therapy as a Novel Approach for Chronic Hepatitis B
Chronic hepatitis B (CHB) is a global health concern, affecting over 250 million people worldwide. Despite the availability of antiviral therapies, a significant proportion of patients fail to achieve sustained virological response, leading to disease progression and an increased risk of liver cirrhosis and hepatocellular carcinoma. Terapia con células madre has emerged as a promising novel approach for CHB, offering the potential for a functional cure by targeting the underlying mechanisms of viral persistence and liver damage.
Mechanisms of Stem Cell Action in Hepatitis B Infection
Stem cells possess unique properties that make them suitable for treating CHB. These include their ability to differentiate into various cell types, incluyendo hepatocitos, which are the primary target of hepatitis B virus (HBV) infección. Stem cells can also secrete paracrine factors that exert immunomodulatory and antiviral effects. By replacing damaged hepatocytes, reducir la inflamación, and inhibiting viral replication, stem cells may contribute to liver regeneration and disease resolution.
Preclinical Studies and Animal Models in Stem Cell Therapy for Hepatitis B
Los estudios preclínicos en modelos animales han demostrado el potencial de terapia con células madre for CHB. In these studies, stem cells have been shown to improve liver function, reducir la carga viral, and promote hepatocyte regeneration. Sin embargo, the optimal stem cell source, método de entrega, and timing of intervention still need to be determined. Further research is necessary to translate these preclinical findings into successful clinical applications.
